Bridge Biotherapeutics Announces the IND Clearance of BBT-176, an EGFR TKI for NSCLC, in South Korea

Following the US FDA's IND clearance, South Korea's MFDS cleared the IND application of BBT-176, submitted in December 2019 BBT-176 will be the company's first drug candidate to launch clinical studies in South Korea In the second half of this year, the company is expected to initiate a...

from PR Newswire: https://ift.tt/2SLZ4S7